Allergic Rhinitis - Pipeline Assessment and Market Forecasts to 2017

Introduction

GlobalData, the industry analysis specialist, has released a new report, “Allergic Rhinitis - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global allergic rhinitis market. The report identifies the key trends shaping and driving the global allergic rhinitis market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to significantly shift the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global allergic rhinitis sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the global allergic rhinitis market. Its scope includes:
- Annualized global allergic rhinitis market revenues data from 2001 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. The key mechanisms of action include histamine antagonists, anti-inflammatory agents, corticosteroids and immunomodulators.
- Analysis of the current and future market competition in the global allergic rhinitis market. The key market players covered are Merck & Co, GlaxoSmithKline, AstraZeneca, Novartis AG, Sanofi-Aventis and HAL Allergy.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for the allergic rhinitis therapeutics market.

Highlights

Reasons to buy

The report will enhance your decision making capability. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global allergic rhinitis market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global allergic rhinitis market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global allergic rhinitis market? – Identify, understand and capitalize

Report Highlights
GlaxoSmithKline
Sanofi-Aventis
AstraZeneca
Merck & Co
[Cerrar las informaciones del articulo de mercado]

TABLE OF CONTENTS

1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Allergic Rhinitis Market: Market Characterization 4
2.1 Disease Overview 4
2.2 Allergic Rhinitis Market Size 4
2.3 Allergic Rhinitis Market Forecast and CAGR 5
2.4 Drivers and Barriers for the Allergic Rhinitis Market 6
2.4.1 Drivers for the Allergic Rhinitis Market 6
2.4.2 Barriers for the Allergic Rhinitis Market 7
2.5 Opportunity and Unmet Need 7
2.6 Key Takeaway 8
3 Allergic Rhinitis Market: Competitive Assessment 9
3.1 Overview 9
3.2 Strategic Competitor Assessment 9
3.3 Product Profile for the Major Marketed Products in the Allergic Rhinitis Market 10
3.3.1 Nasacort AQ (triamcinolone acetonide) 10
3.3.2 Astelin (azelastine hydrochloride) 11
3.3.3 Nasonex (mometasone furoate monohydrate) 12
3.3.4 Singulair (Montelukast Sodium) 14
3.3.5 Rhinocort Aqua (budesonide) 15
3.3.6 Veramyst (fluticasone furoate) 16
3.3.7 Xyzal (levocetirizine dihydrochloride) 18
3.4 Key Takeaway 20
4 Allergic Rhinitis Market: Pipeline Assessment 21
4.1 Overview 21
4.2 Strategic Pipeline Assessment 21
4.2.1 Technology Trends Analytic Framework 21
4.3 Allergic Rhinitis Market – Promising Drugs under Clinical Development 23
4.4 Molecule Profile for Promising Drugs under Clinical Development 23
4.4.1 Bilastine 23
4.4.2 Sublivac (Extracts of allergens) 24
4.4.3 Duonase (Azelastine + Fluticasone) 25
4.4.4 GSK256066 (MDX-010, MDX-101) 25
4.5 Allergic Rhinitis Market – Clinical Pipeline by Mechanism of Action 26
4.5.1 Allergic Rhinitis – Phase III Clinical Pipeline 27
4.5.2 Allergic Rhinitis – Phase II Clinical Pipeline 28
4.5.3 Allergic Rhinitis– Phase I Clinical Pipeline 29
4.5.4 Allergic Rhinitis – Preclinical Pipeline 29
4.5.5 Allergic Rhinitis – List of Terminated Clinical Trials 29
4.6 Key Takeaway 30
5 Allergic Rhinitis Market: Implications for Future Market Competition 31
6 Allergic Rhinitis Market: Future Players in the Allergic Rhinitis Market 32
6.1 Introduction 32
6.2 GlaxoSmithKline 32
6.2.1 Company Overview 32
6.2.2 Business Description 33
6.3 Sanofi-Aventis 34
6.3.1 Company Overview 34
6.4 Novartis AG 35
6.4.1 Company Overview 35
6.4.2 Business Description 35
6.5 AstraZeneca 36
6.5.1 Overview 36
6.5.2 Business Description 36
6.6 Merck & Co 38
6.6.1 Overview 38
6.6.2 Business Description 38
7 Allergic Rhinitis Market: Appendix 39
7.1 Definitions 39
7.2 Scope of Pipeline Research 39
7.3 Abbreviations 39
7.4 Research Methodology 40
7.4.1 Coverage 41
7.4.2 Secondary Research 41
7.4.3 Forecasting 42
7.4.4 Primary Research 45
7.4.5 Expert Panels 45
7.5 Contact Us 45
7.6 Disclaimer 45
7.7 Sources 46
[Cerrar la tabla de contenidos]

LIST OF TABLES

1.1 List of Tables
Table 1: Global Allergic Rhinitis Market Revenue ($bn) 2001- 2009 5
Table 2: Global Allergic Rhinitis Market Revenue ($bn) Forecast 2009-2017 6
Table 3: Major Marketed Products Analysis in the Allergic Rhinitis Market, 2010 19
Table 4: Allergic Rhinitis Therapeutics – Most Promising Drugs Under Clinical Development, 2010 23
Table 5: Allergic Rhinitis Therapeutics – Phase III Clinical Pipeline, 2010 27
Table 6: Allergic Rhinitis Therapeutics – Phase II Clinical Pipeline, 2010 28
Table 7: Allergic Rhinitis Therapeutics – Phase I Clinical Pipeline, 2010 29
Table 8: Allergic Rhinitis Therapeutics – Preclinical Pipeline, 2010 29
Table 9: Allergic Rhinitis Therapeutics – List of Terminated Clinical Trials, 2010 29
Table 10: GlaxoSmithKline - Respiratory Disease, Pipeline Portfolio, 2010 33
Table 11: Sanofi-Aventis - Respiratory Disease, Product Portfolio, 2010 35
Table 12: Novartis AG - Respiratory Disease, Pipeline Portfolio, 2010 36
Table 13: AstraZeneca - Respiratory Disease, Pipeline Portfolio, 2010 37
Table 14: Merck & Co - Respiratory Disease, Pipeline Portfolio, 2010 38
LIST OF FIGURES

1.2 List of Figures
Figure 1: Global Allergic Rhinitis Market 2001–2009 5
Figure 2: Global Allergic Rhinitis Market Forecast 2009–2017 6
Figure 3: Opportunity and Unmet Need in the Allergic Rhinitis Market, 2010 8
Figure 4: Strategic Competitor Assessment of the Major Marketed Products for Allergic Rhinitis, 2010 9
Figure 5: Pipeline Products by Phase of Development, 2010 21
Figure 6: Technology Trends Analytics Framework of the Allergic Rhinitis Pipeline, 2010 22
Figure 7: Technology Trends Analytic Framework of the Allergic Rhinitis Pipeline – Description, 2010 22
Figure 8: Allergic Rhinitis Market – Clinical Pipeline by Mechanism of Action, 2010 26
Figure 9: Allergic Rhinitis Market – Clinical Pipeline by Phase of Development, 2010 27
Figure 10: Implications for Future Market Competition in the Allergic Rhinitis Market, 2010 31
Figure 11: Allergic Rhinitis Therapeutics Market – Clinical Pipeline by Company, 2010 32
Figure 12: GlobalData Methodology 41
Figure 13: GlobalData Market Forecasting Model, 2010 44
[Ocultar lista de tablas / figuras]